{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:25:08Z","timestamp":1791923108733,"version":"4.3.4"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While CAR-T cell therapy has been very successful for treating B cell malignancies, and more recently multiple myeloma, achieving clinical success for acute myeloid leukemia (AML) remains a significant challenge. The examination of current single-antigen targeting CAR-T cell studies for AML illustrates the challenges faced by this therapy: efficacy limitations arise from the heterogeneity of the disease, which often results in antigen escape and subsequent circumvention of single-antigen targeting CAR-T cells, while safety limitations are mainly due to undesired hematological toxicity stemming from the absence of an antigen specifically expressed on AML tumor cells and not on normal hematopoietic cells. This study offers a comprehensive analysis of the most relevant AML surface antigenic markers \u2014CD123, CD33, ADGRE2, CLL-1, TIM-3, CD70, among others\u2014 along with their expression patterns across key cell types, including leukemic blasts, leukemic stem cells, hematopoietic stem cells and progenitors, adult blood cells, and other tissues. Additionally, a variety of strategies for developing CAR-T therapies with improved efficacy and specificity are explored, with dual-antigen targeting CAR-T cell therapies emerging as the most promising approach to overcome the major hurdles observed in single-antigen targeting CAR-T cell therapies. Overall, this review identifies dual-antigen targeting as a therapy holding great prospects in the search of an effective and safe therapeutic approach for AML patients.<\/jats:p>","DOI":"10.1186\/s40164-025-00726-4","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:46:24Z","timestamp":1764269184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting"],"prefix":"10.1186","volume":"14","author":[{"given":"\u00c1ngeles","family":"Oca\u00f1a-Cara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuna","family":"Mutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jort J.","family":"van der Schans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"726_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"4","key":"726_CR2","first-page":"379","volume":"19","author":"JF Yamamoto","year":"2008","unstructured":"Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997\u20132002. Cancer Causes Control. 2008;19(4):379\u201390.","journal-title":"Cancer Causes Control"},{"issue":"7","key":"726_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. \u2018Acute myeloid leukemia: a comprehensive review and 2016 update.\u2019 Blood Cancer J. 2016;6(7):e441.","journal-title":"Blood Cancer J"},{"issue":"7","key":"726_CR4","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730\u20137.","journal-title":"Nat Med"},{"issue":"6","key":"726_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/biot.201100350","volume":"7","author":"VT Hoang","year":"2012","unstructured":"Hoang VT, Zepeda-Moreno A, Ho AD. Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance. Biotechnol J. 2012;7(6):779\u201388.","journal-title":"Biotechnol J"},{"issue":"10","key":"726_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal S, Sekeres MA. Contemporary management of acute myeloid leukemia. JAMA Oncol. 2024;10(10):1417\u201325.","journal-title":"JAMA Oncol"},{"issue":"1","key":"726_CR7","first-page":"46","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75(1):46\u201367.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"726_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3324\/haematol.2010.023184","volume":"95","author":"J Peccatori","year":"2010","unstructured":"Peccatori J, Ciceri F. Allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2010;95(6):857\u20139.","journal-title":"Haematologica"},{"issue":"5","key":"726_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12185-018-2412-8","volume":"107","author":"A Takami","year":"2018","unstructured":"Takami A. Hematopoietic stem cell transplantation for acute myeloid leukemia. Int J Hematol. 2018;107(5):513\u20138.","journal-title":"Int J Hematol"},{"issue":"3","key":"726_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453\u201374.","journal-title":"Blood"},{"issue":"2","key":"726_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.12998\/wjcc.v11.i2.268","volume":"11","author":"YF Chen","year":"2023","unstructured":"Chen YF, Li J, Xu LL, G\u0103man MA, Zou ZY. Allogeneic stem cell transplantation in the treatment of acute myeloid leukemia: an overview of obstacles and opportunities. World J Clin Cases. 2023;11(2):268\u201391.","journal-title":"World J Clin Cases"},{"issue":"2","key":"726_CR12","doi-asserted-by":"publisher","first-page":"300060522107846","DOI":"10.1177\/03000605221078466","volume":"50","author":"CH Lin","year":"2022","unstructured":"Lin CH, Chen TC, Shih YH, Chou CW, Hsu CY, Li PH, et al. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution. J Int Med Res. 2022;50(2):3000605221078466.","journal-title":"J Int Med Res"},{"issue":"1","key":"726_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41408-023-00953-0","volume":"13","author":"M Mozaffari Jovein","year":"2023","unstructured":"Mozaffari Jovein M, Ihorst G, Duque-Afonso J, W\u00e4sch R, Bertz H, Wehr C, et al. Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure. Blood Cancer J. 2023;13(1):179.","journal-title":"Blood Cancer J"},{"issue":"1","key":"726_CR14","first-page":"55","volume":"16","author":"M Mehdizadeh","year":"2022","unstructured":"Mehdizadeh M, Bolourian V, Zamani G, Tavakoli Ardakanii M, Zamani S, Tabarraee M, et al. Survival of patients with acute myeloid leukemia after allogeneic stem cell transplantation: an experience in developing country. Int J Hematol Oncol Stem Cell Res. 2022;16(1):55\u201365.","journal-title":"Int J Hematol Oncol Stem Cell Res."},{"issue":"16","key":"726_CR15","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"1","key":"726_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100826","volume":"46","author":"N Denlinger","year":"2022","unstructured":"Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer. 2022;46(1):100826.","journal-title":"Curr Probl Cancer"},{"issue":"6","key":"726_CR17","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00277-023-05601-y","volume":"103","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang Y, Xue S. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia. Ann Hematol. 2024;103(6):1843\u201357.","journal-title":"Ann Hematol"},{"issue":"1","key":"726_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ejh.14047","volume":"112","author":"V Fetsch","year":"2024","unstructured":"Fetsch V, Zeiser R. Chimeric antigen receptor T cells for acute myeloid leukemia. Eur J Haematol. 2024;112(1):28\u201335.","journal-title":"Eur J Haematol"},{"issue":"15","key":"726_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152615","volume":"16","author":"DJ Chandra","year":"2024","unstructured":"Chandra DJ, Alber B, Saultz JN. The immune resistance signature of acute myeloid leukemia and current immunotherapy strategies. Cancers (Basel). 2024;16(15):2615.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"726_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.20.00475","volume":"39","author":"S Khaldoyanidi","year":"2021","unstructured":"Khaldoyanidi S, Nagorsen D, Stein A, Ossenkoppele G, Subklewe M. Immune biology of acute myeloid leukemia: implications for immunotherapy. J Clin Oncol. 2021;39(5):419\u201332.","journal-title":"J Clin Oncol"},{"issue":"4","key":"726_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"F Perna","year":"2017","unstructured":"Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell. 2017;32(4):506-519.e5.","journal-title":"Cancer Cell"},{"issue":"5","key":"726_CR22","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ymthe.2017.03.034","volume":"25","author":"I Rivi\u00e8re","year":"2017","unstructured":"Rivi\u00e8re I, Sadelain M. Chimeric antigen receptors: a cell and gene therapy perspective. Mol Ther. 2017;25(5):1117\u201324.","journal-title":"Mol Ther"},{"issue":"10","key":"726_CR23","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"C Jordan","year":"2000","unstructured":"Jordan C, Upchurch D, Szilvassy S, Guzman M, Howard D, Pettigrew A, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777\u201384.","journal-title":"Leukemia"},{"issue":"3","key":"726_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjh.12282","volume":"161","author":"S Tettamanti","year":"2013","unstructured":"Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GMP, Cribioli E, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161(3):389\u2013401.","journal-title":"Br J Haematol"},{"issue":"8","key":"726_CR25","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/leu.2014.62","volume":"28","author":"I Pizzitola","year":"2014","unstructured":"Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, et al. Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28(8):1596\u2013605.","journal-title":"Leukemia"},{"issue":"26","key":"726_CR26","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198\u2013208.","journal-title":"Blood"},{"key":"726_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.trsl.2019.05.004","volume":"212","author":"J Yang","year":"2019","unstructured":"Yang J, Wu S, Alachkar H. Characterization of upregulated adhesion GPCRs in acute myeloid leukemia. Transl Res. 2019;212:26\u201335.","journal-title":"Transl Res"},{"issue":"1","key":"726_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, Perna F, K\u00f6hnke T, Schmidt C, Berman S, Augsberger C, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64\u201374.","journal-title":"Leukemia"},{"issue":"11","key":"726_CR29","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell. 2023;41(11):1871-1891.e6.","journal-title":"Cancer Cell"},{"issue":"6","key":"726_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger A, Kramer M, R\u00f6llig C, Thiede C, Bornh\u00e4user M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4(6):e218.","journal-title":"Blood Cancer J"},{"issue":"13","key":"726_CR31","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/0008-5472.CAN-23-2314","volume":"84","author":"D Huang","year":"2024","unstructured":"Huang D, Yu Z, Lu H, Jiang P, Qian X, Han Y, et al. Adhesion GPCR ADGRE2 maintains proteostasis to promote progression in acute myeloid leukemia. Cancer Res. 2024;84(13):2090\u2013108.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"726_CR32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113037","volume":"132","author":"R Shahswar","year":"2018","unstructured":"Shahswar R, Kloos A, Gabdoulline R, Mohanty S, Koenecke C, Wichmann M, et al. Frequency and clinical characteristics associated with putative CAR targets ADGRE2, CCR1, CD70, and LILRB2 in acute myeloid leukemia. Blood. 2018;132(Suppl 1):5259.","journal-title":"Blood"},{"issue":"1","key":"726_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2050-7771-2-4","volume":"2","author":"U Testa","year":"2014","unstructured":"Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4.","journal-title":"Biomark Res"},{"issue":"13","key":"726_CR34","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","volume":"106","author":"DC Taussig","year":"2005","unstructured":"Taussig DC. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106(13):4086\u201392.","journal-title":"Blood"},{"key":"726_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.ai.2017.05.005","volume":"136","author":"HH Lin","year":"2017","unstructured":"Lin HH, Hsiao CC, Pabst C, H\u00e9bert J, Sch\u00f6neberg T, Hamann J. Adhesion GPCRs in regulating immune responses and inflammation. Adv Immunol. 2017;136:163\u2013201.","journal-title":"Adv Immunol"},{"issue":"1","key":"726_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","volume":"27","author":"D Gomes-Silva","year":"2019","unstructured":"Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, et al. CD7 CAR T cells for the therapy of acute myeloid leukemia. Mol Ther. 2019;27(1):272\u201380.","journal-title":"Mol Ther"},{"issue":"10","key":"726_CR37","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","volume":"145","author":"P Lu","year":"2024","unstructured":"Lu P, Zhang X, Yang J, Li J, Qiu L, Gong M, et al. Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood. 2024;145(10):1022\u201333.","journal-title":"Blood"},{"issue":"12","key":"726_CR38","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1182\/blood.V97.12.3683","volume":"97","author":"QL Hao","year":"2001","unstructured":"Hao QL, Zhu J, Price MA, Payne KJ, Barsky LW, Crooks GM. Identification of a novel, human multilymphoid progenitor in cord blood. Blood. 2001;97(12):3683\u201390.","journal-title":"Blood"},{"issue":"1","key":"726_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Xu Y, Li S, Liu J, Xing Y, Xing H, et al. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. J Hematol Oncol. 2018;11(1):60.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"726_CR40","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","volume":"32","author":"H Jetani","year":"2018","unstructured":"Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, et al. CAR t-cells targeting FLT3 have potent activity against FLT3\u2212ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018;32(5):1168\u201379.","journal-title":"Leukemia"},{"issue":"2","key":"726_CR41","first-page":"238","volume":"10","author":"O Rosnet","year":"1996","unstructured":"Rosnet O, B\u00fchring HJ, Marchetto S, Rappold I, Lavagna C, Sainty D, et al. Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996;10(2):238\u201348.","journal-title":"Leukemia"},{"issue":"11","key":"726_CR42","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1182\/blood.V112.11.3900.3900","volume":"112","author":"S Peinert","year":"2008","unstructured":"Peinert S, Ritchie DS, Hoenemann D, Harrison SJ, Guru P, Kershaw MH, et al. Targeting Lewis Y-positive multiple myeloma and acute myeloid leukemia with gene-modified T cells demonstrating memory phenotype. Blood. 2008;112(11):3900.","journal-title":"Blood"},{"issue":"3","key":"726_CR43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/CJI.0b013e31819b7c8e","volume":"32","author":"JA Westwood","year":"2009","unstructured":"Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother. 2009;32(3):292\u2013301.","journal-title":"J Immunother"},{"issue":"5","key":"726_CR44","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/gt.2010.21","volume":"17","author":"S Peinert","year":"2010","unstructured":"Peinert S, Prince HM, Guru PM, Kershaw MH, Smyth MJ, Trapani JA, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 2010;17(5):678\u201386.","journal-title":"Gene Ther"},{"issue":"8","key":"726_CR45","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/glycob\/11.8.677","volume":"11","author":"Y Cao","year":"2001","unstructured":"Cao Y, Merling A, Karsten U, Schwartz-Albiez R. The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes. Glycobiology. 2001;11(8):677\u201383.","journal-title":"Glycobiology"},{"issue":"22","key":"726_CR46","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"ABH Bakker","year":"2004","unstructured":"Bakker ABH, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, et al. C-Type Lectin-Like Molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64(22):8443\u201350.","journal-title":"Cancer Res"},{"issue":"6","key":"726_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, Shima T, Takayanagi IS, Urata S, Miyamoto T, Iwasaki H, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708\u201317.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"726_CR48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.20152008","volume":"214","author":"C Riether","year":"2017","unstructured":"Riether C, Sch\u00fcrch CM, B\u00fchrer ED, Hinterbrandner M, Huguenin AL, Hoepner S, et al. CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017;214(2):359\u201380.","journal-title":"J Exp Med"},{"issue":"4","key":"726_CR49","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138(4):318\u201330.","journal-title":"Blood"},{"issue":"21","key":"726_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213627","volume":"16","author":"U Testa","year":"2024","unstructured":"Testa U, Castelli G, Pelosi E. Membrane antigen targeting in acute myeloid leukemia using antibodies or CAR-T cells. Cancers (Basel). 2024;16(21):3627.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"726_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","volume":"12","author":"H Ma","year":"2019","unstructured":"Ma H, Padmanabhan IS, Parmar S, Gong Y. Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol. 2019;12(1):41.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"726_CR52","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","volume":"108","author":"M Jan","year":"2011","unstructured":"Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA. 2011;108(12):5009\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"726_CR53","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s12185-013-1433-6","volume":"98","author":"Y Kikushige","year":"2013","unstructured":"Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol. 2013;98(6):627\u201333.","journal-title":"Int J Hematol"},{"key":"726_CR54","doi-asserted-by":"publisher","first-page":"1093750","DOI":"10.3389\/fimmu.2023.1093750","volume":"14","author":"G Wu","year":"2023","unstructured":"Wu G, Guo S, Luo Q, Wang X, Deng W, Ouyang G, et al. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Front Immunol. 2023;14:1093750.","journal-title":"Front Immunol"},{"issue":"9","key":"726_CR55","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, Pabst T, H\u00f6pner S, Bacher U, Hinterbrandner M, Banz Y, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020;26(9):1459\u201367.","journal-title":"Nat Med"},{"issue":"1","key":"726_CR56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1600-065X.2009.00774.x","volume":"229","author":"MA Nolte","year":"2009","unstructured":"Nolte MA, Van Olffen RW, Van Gisbergen KPJM, Van Lier RAW. Timing and tuning of CD27\u2013CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev. 2009;229(1):216\u201331.","journal-title":"Immunol Rev"},{"issue":"5","key":"726_CR57","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1021\/acs.molpharmaceut.2c00913","volume":"20","author":"N An","year":"2023","unstructured":"An N, Pan Y, Yang L, Zhang Q, Deng S, Zhang Q, et al. Anti-acute myeloid leukemia activity of CD38-CAR-T cells with PI3K\u03b4 downregulation. Mol Pharm. 2023;20(5):2426\u201335.","journal-title":"Mol Pharm"},{"issue":"16","key":"726_CR58","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","volume":"7","author":"T Glisovic-Aplenc","year":"2023","unstructured":"Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7(16):4418\u201330.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"726_CR59","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2023-184464","volume":"142","author":"S Chen","year":"2023","unstructured":"Chen S, Boardman AP, James SE, van den Brink MRM. CCR1-Targeting CAR T Cells for Acute Myeloid Leukemia. Blood. 2023;142(Suppl 1):4808.","journal-title":"Blood"},{"issue":"26","key":"726_CR60","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1073\/pnas.0704271104","volume":"104","author":"N Hosen","year":"2007","unstructured":"Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007;104(26):11008\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"726_CR61","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jlb.60.5.658","volume":"60","author":"S Su","year":"1996","unstructured":"Su SB, Mukaida N, Wang J, Nomura H, Matsushima K. Preparation of specific polyclonal antibodies to a C-C chemokine receptor, CCR1, and determination of CCR1 expression on various types of leukocytes. J Leukoc Biol. 1996;60(5):658\u201366.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"726_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-019-0956-8","volume":"18","author":"S Duan","year":"2019","unstructured":"Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, et al. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer. 2019;18(1):29.","journal-title":"Mol Cancer"},{"key":"726_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111299","volume":"137","author":"Z Wu","year":"2021","unstructured":"Wu Z, Zhang H, Wu M, Peng G, He Y, Wan N, et al. Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia. Biomed Pharmacother. 2021;137:111299.","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"726_CR64","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18):3138\u201348.","journal-title":"Blood"},{"issue":"15","key":"726_CR65","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor\u2013modified T cells. Blood. 2014;123(15):2343\u201354.","journal-title":"Blood"},{"issue":"Suppl 1","key":"726_CR66","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.811.811","volume":"130","author":"L Budde","year":"2017","unstructured":"Budde L, Song JY, Kim Y, Blanchard S, Wagner J, Stein AS, et al. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Blood. 2017;130(Suppl 1):811.","journal-title":"Blood"},{"issue":"12","key":"726_CR67","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, et al. Cytokine-mediated CAR T therapy resistance in AML. Nat Med. 2024;30(12):3697\u2013708.","journal-title":"Nat Med"},{"key":"726_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01358","volume":"9","author":"S Yao","year":"2019","unstructured":"Yao S, Jianlin C, Yarong L, Botao L, Qinghan W, Hongliang F, et al. Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML. Front Oncol. 2019;9:1358.","journal-title":"Front Oncol"},{"issue":"1","key":"726_CR69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/bc010021y","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody\u2212calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47\u201358.","journal-title":"Bioconjug Chem"},{"key":"726_CR70","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/683065","volume":"2012","author":"A Dutour","year":"2012","unstructured":"Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol. 2012;2012:683065.","journal-title":"Adv Hematol"},{"issue":"12","key":"726_CR71","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3324\/haematol.2010.026310","volume":"95","author":"V Marin","year":"2010","unstructured":"Marin V, Pizzitola I, Agostoni V, Attianese GMPG, Finney H, Lawson A, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica. 2010;95(12):2144\u201352.","journal-title":"Haematologica"},{"issue":"8","key":"726_CR72","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJD, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29(8):1637\u201347.","journal-title":"Leukemia"},{"issue":"1","key":"726_CR73","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"Q Wang","year":"2015","unstructured":"Wang QS, Wang Y, Lv H, Han Q, Fan H, Guo B, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23(1):184\u201391.","journal-title":"Mol Ther"},{"issue":"11","key":"726_CR74","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia. 2021;35(11):3282\u20136.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"726_CR75","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2023-179667","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah NN, Tasian SK, Kohler ME, Hsieh EM, Baumeister SHC, Summers C, et al. CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial. Blood. 2023;142(Suppl 1):771.","journal-title":"Blood"},{"issue":"9","key":"726_CR76","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","volume":"25","author":"H Tashiro","year":"2017","unstructured":"Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, et al. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther. 2017;25(9):2202\u201313.","journal-title":"Mol Ther"},{"issue":"1","key":"726_CR77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11(1):7.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"726_CR78","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang P, Li Z, He Y, Gan W, Jiang H. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin Cancer Res. 2021;27(13):3549\u201355.","journal-title":"Clin Cancer Res"},{"key":"726_CR79","doi-asserted-by":"crossref","unstructured":"Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, et al. CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia. Blood. 2025;2025029532.","DOI":"10.1182\/blood.2025029532"},{"issue":"7","key":"726_CR80","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","volume":"72","author":"J Cheng","year":"2023","unstructured":"Cheng J, Ge T, Zhu X, Wang J, Zeng Y, Mu W, et al. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunol Immunother. 2023;72(7):2331\u201346.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"726_CR81","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick MB, Silva H, Scarf\u00f2 I, Larson R, Choi BD, Bouffard AA, et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022;40(5):494-508.e5.","journal-title":"Cancer Cell"},{"issue":"Suppl 1","key":"726_CR82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181251","volume":"142","author":"JM Unglaub","year":"2023","unstructured":"Unglaub JM, Brinkmann B, Chen Q, Sedloev D, Bruch PM, Kolb C, et al. Improving anti-tumor efficacy of CAR T-cell therapy for acute myeloid leukemia (AML): results from a multi-drug interaction screening approach. Blood. 2023;142(Suppl 1):5969.","journal-title":"Blood"},{"issue":"8","key":"726_CR83","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/leu.2017.147","volume":"31","author":"L Chen","year":"2017","unstructured":"Chen L, Mao H, Zhang J, Chu J, Devine S, Caligiuri MA, et al. Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia. 2017;31(8):1830\u20134.","journal-title":"Leukemia"},{"issue":"2","key":"726_CR84","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3324\/haematol.2022.281456","volume":"108","author":"LM Niswander","year":"2023","unstructured":"Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, et al. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia. Haematologica. 2023;108(2):457\u201371.","journal-title":"Haematologica"},{"issue":"12","key":"726_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.73","volume":"5","author":"T Yoshida","year":"2016","unstructured":"Yoshida T, Mihara K, Takei Y, Yanagihara K, Kubo T, Bhattacharyya J, et al. All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia. Clin Transl Immunol. 2016;5(12):e116.","journal-title":"Clin Transl Immunol"},{"key":"726_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580328","volume":"11","author":"L Driouk","year":"2020","unstructured":"Driouk L, Gicobi JK, Kamihara Y, Rutherford K, Dranoff G, Ritz J, et al. Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Front Immunol. 2020;11:580328.","journal-title":"Front Immunol"},{"issue":"9","key":"726_CR87","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","volume":"20","author":"WHS Lee","year":"2021","unstructured":"Lee WHS, Ye Z, Cheung AMS, Goh YPS, Oh HLJ, Rajarethinam R, et al. Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T cells. Mol Cancer Ther. 2021;20(9):1702\u201312.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"726_CR88","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122\u20139.","journal-title":"Mol Ther"},{"issue":"1","key":"726_CR89","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol Res. 2019;7(1):100\u201312.","journal-title":"Cancer Immunol Res"},{"issue":"Suppl 1","key":"726_CR90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128020","volume":"134","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, Brayer JB, Poire X, Havelange V, Awada A, Lewalle P, et al. Results from the completed dose-escalation of the hematological arm of the phase I think study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapse\/refractory acute myeloid leukemia and myelodysplastic syndrome patients. Blood. 2019;134(Suppl 1):3826.","journal-title":"Blood"},{"issue":"24","key":"726_CR91","doi-asserted-by":"publisher","first-page":"15907","DOI":"10.3390\/ijms232415907","volume":"23","author":"S Maurer","year":"2022","unstructured":"Maurer S, Zhong X, Prada BD, Mascarenhas J, de Andrade LF. The latest breakthroughs in immunotherapy for acute myeloid leukemia, with a special focus on NKG2D ligands. Int J Mol Sci. 2022;23(24):15907.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"726_CR92","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","volume":"14","author":"Q Cui","year":"2021","unstructured":"Cui Q, Qian C, Xu N, Kang L, Dai H, Cui W, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):82.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"726_CR93","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"726_CR94","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.3390\/cancers15102713","volume":"15","author":"E Atilla","year":"2023","unstructured":"Atilla E, Benabdellah K. The black hole: CAR T cell therapy in AML. Cancers (Basel). 2023;15(10):2713.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"726_CR95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008429","volume":"12","author":"W Ouyang","year":"2024","unstructured":"Ouyang W, Jin SW, Xu N, Liu WY, Zhao H, Zhang L, et al. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J Immunother Cancer. 2024;12(4):e008429.","journal-title":"J Immunother Cancer"},{"key":"726_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116132","volume":"171","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li Y, Gao Y, Zhang P, Jing Q, Zhang Y, et al. Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective. Biomed Pharmacother. 2024;171:116132.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"726_CR97","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3892\/mmr.2021.11847","volume":"23","author":"G Lin","year":"2021","unstructured":"Lin G, Zhang Y, Yu L, Wu D. Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed\/refractory acute myeloid leukemia. Mol Med Rep. 2021;23(3):208.","journal-title":"Mol Med Rep"},{"issue":"2","key":"726_CR98","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/BST20150291","volume":"44","author":"OO Yeku","year":"2016","unstructured":"Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44(2):412\u20138.","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"726_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/acg2.84","volume":"3","author":"M Chmielewski","year":"2020","unstructured":"Chmielewski M, Abken H. TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation. Adv Cell Gene Ther. 2020;3(3):e84.","journal-title":"Adv Cell Gene Ther"},{"key":"726_CR100","doi-asserted-by":"publisher","first-page":"1260470","DOI":"10.3389\/fimmu.2023.1260470","volume":"14","author":"L P\u00e9rez-Amill","year":"2023","unstructured":"P\u00e9rez-Amill L, Bataller \u00c0, Delgado J, Esteve J, Juan M, Klein-Gonz\u00e1lez N. Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development. Front Immunol. 2023;14:1260470.","journal-title":"Front Immunol"},{"key":"726_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00241","volume":"9","author":"S Di","year":"2019","unstructured":"Di S, Zhou M, Pan Z, Sun R, Chen M, Jiang H, et al. Combined adjuvant of poly I:C improves antitumor effects of CAR-T cells. Front Oncol. 2019;9:241.","journal-title":"Front Oncol"},{"issue":"1","key":"726_CR102","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2055703","volume":"11","author":"Q Yang","year":"2022","unstructured":"Yang Q, Hao J, Chi M, Wang Y, Xin B, Huang J, et al. Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. Oncoimmunology. 2022;11(1):2055703.","journal-title":"Oncoimmunology"},{"issue":"1","key":"726_CR103","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2338558","volume":"13","author":"A Tapia-Galisteo","year":"2024","unstructured":"Tapia-Galisteo A, S\u00e1nchez-Rodr\u00edguez I, Narbona J, Iglesias-Hern\u00e1ndez P, Arag\u00f3n-Garc\u00eda S, Jim\u00e9nez-Reinoso A, et al. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-\u03b2 and PD-L1 enhances antitumor responses. Oncoimmunology. 2024;13(1):2338558.","journal-title":"Oncoimmunology"},{"issue":"2","key":"726_CR104","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al. Hla-independent T cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28(2):345\u201352.","journal-title":"Nat Med"},{"key":"726_CR105","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.imlet.2019.06.002","volume":"212","author":"M Zabel","year":"2019","unstructured":"Zabel M, Tauber PA, Pickl WF. The making and function of CAR cells. Immunol Lett. 2019;212:53\u201369.","journal-title":"Immunol Lett"},{"key":"726_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.836549","volume":"13","author":"L Halim","year":"2022","unstructured":"Halim L, Das KK, Larcombe-Young D, Ajina A, Candelli A, Benjamin R, et al. Engineering of an avidity-optimized CD19-specific parallel chimeric antigen receptor that delivers dual CD28 and 4\u20131BB co-stimulation. Front Immunol. 2022;13:836549.","journal-title":"Front Immunol"},{"issue":"9","key":"726_CR107","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","volume":"17","author":"D Kabelitz","year":"2020","unstructured":"Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us. Cell Mol Immunol. 2020;17(9):925\u201339.","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"726_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14123005","volume":"14","author":"D Lee","year":"2022","unstructured":"Lee D, Rosenthal CJ, Penn NE, Dunn ZS, Zhou Y, Yang L. Human \u03b3\u03b4 T cell subsets and their clinical applications for cancer immunotherapy. Cancers (Basel). 2022;14(12):3005.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"726_CR109","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005400","volume":"10","author":"D S\u00e1nchez Mart\u00ednez","year":"2022","unstructured":"S\u00e1nchez Mart\u00ednez D, Tirado N, Mensurado S, Mart\u00ednez-Moreno A, Romec\u00edn P, Guti\u00e9rrez Ag\u00fcera F, et al. Generation and proof-of-concept for allogeneic CD123 CAR-Delta one T (DOT) cells in acute myeloid leukemia. J Immunother Cancer. 2022;10(9):e005400.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 1","key":"726_CR110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190357","volume":"142","author":"A Dwivedi","year":"2023","unstructured":"Dwivedi A, Fu L, Chien CD, Pouzolles M, Shah NN, Taylor N. Engineering off-the-shelf gamma delta CAR T cells for the treatment of acute myeloid leukemia. Blood. 2023;142(Suppl 1):4827.","journal-title":"Blood"},{"issue":"1","key":"726_CR111","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, et al. Strategies to enhance CAR-T persistence. Biomark Res. 2022;10(1):86.","journal-title":"Biomark Res"},{"issue":"24","key":"726_CR112","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750\u20139.","journal-title":"Blood"},{"issue":"1","key":"726_CR113","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Si X, Shao M, Teng X, Xiao G, Huang H. Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. J Hematol Oncol. 2022;15(1):38.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"726_CR114","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12(1):409.","journal-title":"Nat Commun"},{"issue":"10","key":"726_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102940","volume":"12","author":"F Marchesi","year":"2020","unstructured":"Marchesi F, Vignali D, Manini B, Rigamonti A, Monti P. Manipulation of glucose availability to boost cancer immunotherapies. Cancers (Basel). 2020;12(10):2940.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"726_CR116","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/CM9.0000000000003046","volume":"137","author":"S Liu","year":"2024","unstructured":"Liu S, Zhao Y, Gao Y, Li F, Zhang Y. Targeting metabolism to improve CAR-T cells therapeutic efficacy. Chin Med J (Engl). 2024;137(8):909\u201320.","journal-title":"Chin Med J (Engl)"},{"key":"726_CR117","doi-asserted-by":"publisher","first-page":"1145441","DOI":"10.3389\/fimmu.2023.1145441","volume":"14","author":"L Tang","year":"2023","unstructured":"Tang L, Kong Y, Wang H, Zou P, Sun T, Liu Y, et al. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia. Front Immunol. 2023;14:1145441.","journal-title":"Front Immunol"},{"key":"726_CR118","doi-asserted-by":"publisher","first-page":"1335424","DOI":"10.3389\/fimmu.2024.1335424","volume":"15","author":"S Smirnov","year":"2024","unstructured":"Smirnov S, Mateikovich P, Samochernykh K, Shlyakhto E. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol. 2024;15:1335424.","journal-title":"Front Immunol"},{"key":"726_CR119","doi-asserted-by":"publisher","first-page":"1200914","DOI":"10.3389\/fonc.2023.1200914","volume":"13","author":"E Moreno-Cortes","year":"2023","unstructured":"Moreno-Cortes E, Franco-Fuquen P, Garcia-Robledo JE, Forero J, Booth N, Castro JE. ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype. Front Oncol. 2023;13:1200914.","journal-title":"Front Oncol"},{"issue":"3","key":"726_CR120","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u20139.","journal-title":"Nat Med"},{"issue":"18","key":"726_CR121","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673\u201383.","journal-title":"N Engl J Med"},{"key":"726_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.564099","volume":"11","author":"X Zhou","year":"2020","unstructured":"Zhou X, Tu S, Wang C, Huang R, Deng L, Song C, et al. Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas. Front Immunol. 2020;11:564099.","journal-title":"Front Immunol"},{"issue":"12","key":"726_CR123","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41417-020-00284-3","volume":"28","author":"W Warda","year":"2021","unstructured":"Warda W, Da Rocha MN, Trad R, Haderbache R, Salma Y, Bouquet L, et al. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Ther. 2021;28(12):1365\u201375.","journal-title":"Cancer Gene Ther"},{"issue":"17","key":"726_CR124","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","volume":"129","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017;129(17):2395\u2013407.","journal-title":"Blood"},{"issue":"Suppl 15","key":"726_CR125","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","volume":"36","author":"JS Abramson","year":"2018","unstructured":"Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J Clin Oncol. 2018;36(Suppl 15):7505.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"726_CR126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.887.887","volume":"130","author":"C Graham","year":"2017","unstructured":"Graham C, Yallop D, Jozwik A, Patten P, Dunlop A, Ellard R, et al. Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood. 2017;130(Suppl 1):887.","journal-title":"Blood"},{"issue":"8","key":"726_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.61","volume":"6","author":"M Cartellieri","year":"2016","unstructured":"Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6(8):e458.","journal-title":"Blood Cancer J"},{"issue":"5","key":"726_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051302","volume":"12","author":"C Arndt","year":"2020","unstructured":"Arndt C, Fasslrinner F, Loureiro LR, Koristka S, Feldmann A, Bachmann M. Adaptor CAR platforms\u2014next generation of T cell-based cancer immunotherapy. Cancers. 2020;12(5):1302.","journal-title":"Cancers"},{"issue":"74","key":"726_CR129","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl3995","volume":"7","author":"Q Xiao","year":"2022","unstructured":"Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS, Su X. Size-dependent activation of CAR-T cells. Sci Immunol. 2022;7(74):eabl3995.","journal-title":"Sci Immunol"},{"key":"726_CR130","first-page":"408","volume":"17","author":"S Loff","year":"2020","unstructured":"Loff S, Dietrich J, Meyer JE, Riewaldt J, Spehr J, von Bonin M, et al. Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia. Mol Ther. 2020;17:408\u201320.","journal-title":"Mol Ther"},{"issue":"1","key":"726_CR131","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymthe.2005.07.688","volume":"13","author":"Y Zhao","year":"2006","unstructured":"Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther. 2006;13(1):151\u20139.","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"726_CR132","first-page":"1359","volume":"130","author":"KD Cummins","year":"2017","unstructured":"Cummins KD, Frey N, Nelson AM, Schmidt A, Luger S, Isaacs RE, et al. Treating Relapsed \/ Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells. Blood. 2017;130(Suppl 1):1359.","journal-title":"Blood"},{"issue":"10","key":"726_CR133","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"726_CR134","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139\u201349.","journal-title":"J Exp Med"},{"issue":"2","key":"726_CR135","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00262-023-03605-1","volume":"73","author":"A Sharma","year":"2024","unstructured":"Sharma A, Ren X, Rosato A, Sangiolo D, Wang Z, Tettamanti S, et al. Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy. Cancer Immunol Immunother. 2024;73(2):21.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"726_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M, et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Exp Hematol Oncol. 2025;14(1):1.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"726_CR137","first-page":"42","volume":"52","author":"F Gierschek","year":"2024","unstructured":"Gierschek F, Schlueter J, K\u00fchnel I, Feigl FF, Schmiedel D, Pr\u00fcfer M, et al. Empowering natural killer cells to combat acute myeloid leukemia: perspective on CAR-NK cell therapy. Transfus Med Hemother. 2024;52(1):42\u201360.","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"726_CR138","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10238-025-01559-5","volume":"25","author":"M Rady","year":"2025","unstructured":"Rady M, Mostafa M, Dida G, Sabet F, Abou-Aisha K, Watzl C. Adoptive NK cell therapy in AML: progress and challenges. Clin Exp Med. 2025;25(1):41.","journal-title":"Clin Exp Med"},{"issue":"3","key":"726_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030580","volume":"14","author":"L Arranz","year":"2022","unstructured":"Arranz L. The hematology of tomorrow is here\u2014preclinical models are not: cell therapy for hematological malignancies. Cancers. 2022;14(3):580.","journal-title":"Cancers"},{"key":"726_CR140","doi-asserted-by":"crossref","unstructured":"Biondi M, Tettamanti S, Galimberti S, Cerina B, Tomasoni C, Piazza R, et al. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden. Blood. 2023","DOI":"10.1182\/blood.2022018330"},{"key":"726_CR141","doi-asserted-by":"publisher","first-page":"1192333","DOI":"10.3389\/fimmu.2023.1192333","volume":"14","author":"G Alberti","year":"2023","unstructured":"Alberti G, Arsuffi C, Pievani A, Salerno D, Mantegazza F, Dazzi F, et al. Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche. Front Immunol. 2023;14:1192333.","journal-title":"Front Immunol"},{"issue":"12","key":"726_CR142","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1182\/bloodadvances.2022008762","volume":"7","author":"VM Perriello","year":"2023","unstructured":"Perriello VM, Rotiroti MC, Pisani I, Galimberti S, Alberti G, Pianigiani G, et al. IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML. Blood Adv. 2023;7(12):2855\u201371.","journal-title":"Blood Adv"},{"issue":"8","key":"726_CR143","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2020006921","volume":"137","author":"S Willier","year":"2021","unstructured":"Willier S, Roth\u00e4mel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood. 2021;137(8):1037\u201349.","journal-title":"Blood"},{"issue":"9","key":"726_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092523","volume":"12","author":"RJ Cronk","year":"2020","unstructured":"Cronk RJ, Zurko J, Shah NN. Bispecific chimeric antigen receptor T cell therapy for B cell malignancies and multiple myeloma. Cancers. 2020;12(9):2523.","journal-title":"Cancers"},{"issue":"6","key":"726_CR145","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","volume":"32","author":"JC Petrov","year":"2018","unstructured":"Petrov JC, Wada M, Pinz KG, Yan LE, Chen KH, Shuai X, et al. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia. 2018;32(6):1317\u201326.","journal-title":"Leukemia"},{"issue":"1","key":"726_CR146","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00262-024-03847-7","volume":"74","author":"H Ma","year":"2024","unstructured":"Ma H, Yan Z, Gu R, Xu Y, Qiu S, Xing H, et al. Loop33 \u00d7 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia. Cancer Immunol Immunother. 2024;74(1):20.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"726_CR147","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcyt.2021.10.007","volume":"24","author":"PA Atilla","year":"2022","unstructured":"Atilla PA, McKenna MK, Watanabe N, Mamonkin M, Brenner MK, Atilla E. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. Cytotherapy. 2022;24(3):282\u201390.","journal-title":"Cytotherapy"},{"issue":"Suppl 1","key":"726_CR148","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1182\/blood-2022-170503","volume":"140","author":"L Scherer","year":"2022","unstructured":"Scherer L, Tat C, Sauer T, Tashiro H, Naik S, Velasquez MP, et al. LigandCD70.CAR as a platform for dual-targeting CAR T cells for acute myeloid leukemia. Blood. 2022;140(Suppl 1):7396\u20137.","journal-title":"Blood"},{"issue":"1","key":"726_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01541-9","volume":"21","author":"K Li","year":"2022","unstructured":"Li K, Wu H, Pan W, Guo M, Qiu D, He Y, et al. A novel approach for relapsed\/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CAR T cells and gilteritinib. Mol Cancer. 2022;21(1):66.","journal-title":"Mol Cancer"},{"key":"726_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101695","volume":"34","author":"D Xie","year":"2023","unstructured":"Xie D, Jin X, Sun R, Zhang M, Lu W, Cao X, et al. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape. Transl Oncol. 2023;34:101695.","journal-title":"Transl Oncol"},{"issue":"1","key":"726_CR151","doi-asserted-by":"publisher","first-page":"2248826","DOI":"10.1080\/2162402X.2023.2248826","volume":"12","author":"X Jin","year":"2023","unstructured":"Jin X, Xie D, Sun R, Lu W, Xiao X, Yu Y, et al. CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells. Oncoimmunology. 2023;12(1):2248826.","journal-title":"Oncoimmunology"},{"issue":"Suppl 1","key":"726_CR152","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu F, Cao Y, Pinz K, Ma Y, Wada M, Chen K, et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood. 2018;132(Suppl 1):901.","journal-title":"Blood"},{"key":"726_CR153","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana S, Gill S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;10:697.","journal-title":"Front Oncol"},{"key":"726_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.695051","volume":"12","author":"R Limongello","year":"2021","unstructured":"Limongello R, Marra A, Mancusi A, Bonato S, Hoxha E, Ruggeri L, et al. Novel immune cell-based therapies to eradicate high-risk acute myeloid leukemia. Front Immunol. 2021;12:695051.","journal-title":"Front Immunol"},{"issue":"6","key":"726_CR155","first-page":"650","volume":"23","author":"A Ghamari","year":"2021","unstructured":"Ghamari A, Pakzad P, Majd A, Ebrahimi M, Hamidieh AA. Design and production an effective bispecific tandem chimeric antigen receptor on T cells against CD123 and folate receptor \u00df towards B-acute myeloid leukaemia blasts. Cell J. 2021;23(6):650\u20137.","journal-title":"Cell J"},{"issue":"1","key":"726_CR156","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.14104","volume":"112","author":"X Wang","year":"2024","unstructured":"Wang X, Bian M, Lin G, Yu L, Zhang Y, Wu D. Tandem bispecific CD123\/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia. Eur J Haematol. 2024;112(1):83\u201393.","journal-title":"Eur J Haematol"},{"key":"726_CR157","doi-asserted-by":"publisher","DOI":"10.2450\/BloodTransfus.786","author":"H Wang","year":"2024","unstructured":"Wang H, Feng S, Zhu Y, Zhang Y, Zhou Z, Nian Z, et al. The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia. Blood Transfus. 2024. https:\/\/doi.org\/10.2450\/BloodTransfus.786.","journal-title":"Blood Transfus"},{"issue":"2","key":"726_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200797","volume":"32","author":"K Teppert","year":"2024","unstructured":"Teppert K, Yonezawa Ogusuku IE, Brandes C, Herbel V, Winter N, Werchau N, et al. CAR\u2019TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment. Mol Ther Oncolytics. 2024;32(2):200797.","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"726_CR159","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31(1):71\u20135.","journal-title":"Nat Biotechnol"},{"issue":"20","key":"726_CR160","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1158\/1078-0432.CCR-23-0132","volume":"29","author":"JJ van der Schans","year":"2023","unstructured":"van der Schans JJ, Wang Z, van Arkel J, van Schaik T, Katsarou A, Ruiter R, et al. Specific targeting of multiple myeloma by dual split-signaling chimeric antigen receptor T cells directed against CD38 and CD138. Clin Cancer Res. 2023;29(20):4219\u201329.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"726_CR161","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1182\/blood-2023-180799","volume":"142","author":"JJ Van Der Schans","year":"2023","unstructured":"Van Der Schans JJ, Vishwasrao P, Van Gils N, Hosny M, Wang Z, Van Arkel J, et al. Dual split-signaling TIM3+CLEC12a targeting CAR T-cells with optimized signaling as a safe potential therapy for acute myeloid leukemia. Blood. 2023;142(Suppl 1):883.","journal-title":"Blood"},{"issue":"Suppl 1","key":"726_CR162","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1182\/blood-2023-180890","volume":"142","author":"Y Wang","year":"2023","unstructured":"Wang Y, Lu W, Rohrbacher L, Flaswinkel H, Emhardt AJ, Magno G, et al. CD33-TIM3 dual CAR T cells: enhancing specificity while maintaining efficacy against AML. Blood. 2023;142(Suppl 1):3449.","journal-title":"Blood"},{"issue":"10","key":"726_CR163","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713\u201323.","journal-title":"Blood"},{"key":"726_CR164","volume":"31","author":"JC Boucher","year":"2023","unstructured":"Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T, et al. Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther. 2023;31:100751.","journal-title":"Mol Ther"},{"issue":"12","key":"726_CR165","doi-asserted-by":"publisher","first-page":"10189","DOI":"10.1007\/s00432-023-04865-1","volume":"149","author":"L Sun","year":"2023","unstructured":"Sun L, Jiang G, Ng YY, Xiao L, Du Z, Wang S, et al. T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo. J Cancer Res Clin Oncol. 2023;149(12):10189\u2013201.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"726_CR166","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/blood.2023021054","volume":"143","author":"T Dao","year":"2024","unstructured":"Dao T, Xiong G, Mun SS, Meyerberg J, Korontsvit T, Xiang J, et al. A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood. 2024;143(6):507\u201321.","journal-title":"Blood"},{"issue":"1","key":"726_CR167","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1158\/2643-3230.BCD-23-0258","volume":"6","author":"S Jambon","year":"2025","unstructured":"Jambon S, Sun J, Barman S, Muthugounder S, Bito XR, Shadfar A, et al. CD33\u2013CD123 IF-THEN gating reduces toxicity while enhancing the specificity and memory phenotype of AML-targeting CAR-T cells. Blood Cancer Discov. 2025;6(1):55\u201372.","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"726_CR168","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell. 2019;35(3):489-503.e8.","journal-title":"Cancer Cell"},{"issue":"215","key":"726_CR169","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov VD, Themeli M, Sadelain M. PD-1\u2013 and CTLA-4\u2013based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.","journal-title":"Sci Transl Med"},{"issue":"6","key":"726_CR170","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","volume":"2","author":"RM Richards","year":"2021","unstructured":"Richards RM, Zhao F, Freitas KA, Parker KR, Xu P, Fan A, et al. NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity. Blood Cancer Discov. 2021;2(6):648\u201365.","journal-title":"Blood Cancer Discov"},{"issue":"Suppl 1","key":"726_CR171","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1182\/blood-2024-205192","volume":"144","author":"R Zhang","year":"2024","unstructured":"Zhang R, Zhao Y, Zhao M. Modified dual CLL1-CD15 and CLL1-CD16 icar-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia. Blood. 2024;144(Suppl 1):372.","journal-title":"Blood"},{"key":"726_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1493329","volume":"16","author":"B DiAndreth","year":"2025","unstructured":"DiAndreth B, Nesterenko PA, Winters AG, Flynn AD, Jette CA, Suryawanshi V, et al. Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy. Front Immunol. 2025;16:1493329.","journal-title":"Front Immunol"},{"issue":"4","key":"726_CR173","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","volume":"9","author":"G de Oliveira Canedo","year":"2025","unstructured":"de Oliveira Canedo G, Roddie C, Amrolia PJ. Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Blood Adv. 2025;9(4):704\u201321.","journal-title":"Blood Adv"},{"issue":"10","key":"726_CR174","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/icb.2015.59","volume":"93","author":"MY Bilal","year":"2015","unstructured":"Bilal MY, Vacaflores A, Houtman JC. Optimization of methods for the genetic modification of human T cells. Immunol Cell Biol. 2015;93(10):896\u2013908.","journal-title":"Immunol Cell Biol"},{"key":"726_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780442","volume":"12","author":"PH Mehta","year":"2021","unstructured":"Mehta PH, Fiorenza S, Koldej RM, Jaworowski A, Ritchie DS, Quinn KM. T cell fitness and autologous CAR T cell therapy in haematologic malignancy. Front Immunol. 2021;12:780442.","journal-title":"Front Immunol"},{"issue":"6","key":"726_CR176","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390.","journal-title":"Nat Med"},{"issue":"5","key":"726_CR177","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang H, et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 2023;33(5):341\u201354.","journal-title":"Cell Res"},{"issue":"9","key":"726_CR178","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina A, Maher J. Strategies to address chimeric antigen receptor tonic signaling. Mol Cancer Ther. 2018;17(9):1795\u2013815.","journal-title":"Mol Cancer Ther"},{"issue":"7952","key":"726_CR179","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim WJ, Lareau C, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615(7952):507\u201316.","journal-title":"Nature"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00726-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:02:24Z","timestamp":1764273744000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00726-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":179,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00726-4","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T.M. has received research support from Janssen Pharmaceuticals, Genmab, Takeda, Novartis and ONK Therapeutics. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}